Category Archives: Stell Cell Research


Stem Cell Clinic > Stell Cell Research

Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers

By Stell Cell Research

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders, has reported positive results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of CVN293 in healthy volunteers. CVN293 is designed to inhibit KCNK13, a potentially novel target involved in activating the NLRP3 inflammasome, with the aim of reducing neuroinflammation and attenuating disease progression in a variety of neurodegenerative disorders. KCNK13 was identified by Cerevance’s proprietary NETSseq platform.

Read the original post:
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

By Stell Cell Research

MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company’s technological and manufacturing strategies.

More here:
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

By Stell Cell Research

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.

Read more:
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

→←